Precept Management’s Charles River Laboratories CRL Stock Holding History

Precept Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,100	Closed	-$4.94M	–	56
2021 Q4	$4.94M	Hold	13,100	–	–	1.94%	13
2021 Q3	$5.41M	Hold	13,100	–	–	2.52%	11
2021 Q2	$4.85M	Sell	13,100 -900	-6%	-$301K	2.04%	15
2021 Q1	$4.06M	Sell	14,000 -76,000	-84%	-$21.1M	2.77%	11
2020 Q4	$22.5M	Buy	90,000 +5,000	+6%	+$1.19M	9.11%	2
2020 Q3	$19.2M	Buy	85,000 +7,700	+10%	+$1.6M	4.72%	5
2020 Q2	$13.5M	Buy	77,300 +75,000	+3,261%	+$12M	2.58%	11
2020 Q1	$290K	Sell	2,300 -27,800	-92%	-$4.17M	0.04%	109
2019 Q4	$4.6M	Buy	30,100 +7,600	+34%	+$1.05M	2.22%	15
2019 Q3	$2.98M	Hold	22,500	–	–	1.79%	17
2019 Q2	$3.19M	Buy	22,500 +2,500	+13%	+$339K	1%	22
2019 Q1	$2.9M	Buy	+20,000	New	+$2.63M	1.31%	24

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Precept Management's CRL Position: Q1 2022 in Review

Precept Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 13,100 shares — an estimated $4.94M sold.

Precept Management first reported a position in CRL in Q1 2019 and held it in 12 quarters. The position peaked at $22.5M in Q4 2020. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Precept Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
Precept Management sold 13,100 Charles River Laboratories shares in Q1 2022, an estimated $4.94M.
Precept Management first reported a position in Charles River Laboratories in Q1 2019 and held it in 12 quarters.
Precept Management's Charles River Laboratories position peaked at $22.5M in Q4 2020.
644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Precept Management's 13F filing for Q1 2022, filed 16 May 2022.